Vivek Subbiah: Future of cancer research is bright!

Vivek Subbiah shared on X/Twitter:

“Future of cancer research is bright! So nice to see the next generation of cancer researchers at AACR24. Kudos to AACR for encouraging > 150 undergraduate students in the poster competition. Looking forward to judge a poster session for junior fellows and early career researchers.”

Source: Vivek Subbiah/X

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center.
Dr. Vivek Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in-human and practice-changing studies that directly led to approvals from the FDA, European Medicines Agency, and other agencies across the world. He is an expert in tumor agnostic precision oncology and leads the BRAF and RET tissue agnostic studies to FDA approval.